Quadrant 4 System Corporation on Wednesday announced that HealthSmart will implement Quadrant 4’s QHIX Benefits Administration and Private Health Exchange capabilities. Read More »
The Lehigh Valley Business Coalition on Healthcare and Capital BlueCross have extended their partnership Read More »
A Prime Therapeutics, LLC study analyzed their controlled substance (CS) scores that are used to identify high-risk drug use and found a correlation between CS scores and health outcomes. Read More »
TeaserOrexo AB announced Tuesday that it has began the launch of a new higher dosage of ZUBSOLV, a drug that was recently issued a new U.S. patent. Read More »
PatientsLikeMe, an online patient network, is helping Walgreens make it easier for customers to understand the effects their medications may have on them, PatientsLikeMe said Wednesday. Read More »
Cigna-HealthSpring on Wednesday announced a new partnership with Telcare that will expand health care services for its Texas Medicaid STAR+PLUS membership as a part of an attempt to improve quality of life and reduce costs for its beneficiaries with diabetes. Telcare is a leader in mobile diabetes management solutions and will provide engagement and monitoring services for beneficiaries with diabetes enrolled with Cigna-HealthSpring under the Texas Medicaid STAR+PLUS Program. Read More »
The FDA's plan to let generic drug companies update their labels showed new signs of life this week. Read More »
A commentary published Friday on the HealthAffairs.org blog raises concerns about the possible impact of new cholesterol drugs on the U.S. health care system. Read More »
TeaserMcKesson Corporation announced Tuesday that Bansi Nagji was appointed executive vice president of corporate strategy and business development; his predecessor, Brian Tyler, was promoted to president of North American Pharmaceutical Distribution and Services.HeadlineMcKesson appoints Bansi Nagji to succeed Brian Tyler as president of corporate strategy and business developmentBody Prior to McKesson, Nagji led the U.S. Read More »
Recent data from the annual Truven Health Analytics U.S. Benchmarks and Trends reports for employers and health plans predict that employee out-of-pocket costs will experience double-digit growth, and commercial-payer costs will grow at a more modest rate. Read More »
Teva Pharmaceutical announces the launch of generic Lovenox (enoxaparin sodium injection) in the U.S. Read More »
The U.S. Food and Drug Administration released five new draft documents last week on compounding and repackaging to help commercial entities comply with important public health laws. Read More »
The U.S. Food and Drug Administration on Feb. 13 approved Lenvima (lenvatinib) to as a treatment for patients with progressive, differentiated thyroid cancer (DTC) whose disease progressed despite radioactive iodine therapy. Read More »
A recent study from the U.S. Centers for Disease Control and Prevention (CDC) has found a decline in the efficacy of the flu vaccine against the virus during the 2014-2015 season. Read More »
The U.S. Generic Drug Market Outlook 2018 recently revealed a steadily growing market for generics Read More »
Novartis said on Friday that the U.S. Food and Drug Administration (FDA) granted priority review designation to LCZ696, a test drug for the treatment of heart failure with reduced ejection fraction (HFrEF). Read More »
Pfizer said on Friday that the U.S. Food and Drug Administration has agreed to review the New Drug Application (NDA) for ALO-02, an abuse-deterrent opioid for chronic pain. Read More »
Cumberland Pharmaceuticals said on Wednesday that it is entering a Phase II development program for Boxaban (ifetroban), an oral capsule for the treatment of aspirin-exacerbated respiratory disease (AERD). Read More »
The Alliance to Prevent the Abuse of Medicines recently said the group supports the Obama administration’s proposed budget item to fund efforts toward the prevention and reduction of prescription drug abuse. Read More »
Amgen said on Wednesday that its Biologics License Application (BLA) for talimogene laherparepvec will be reviewed by the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) and the Cellular, Tissue and Gene Therapies Advisory Committee. Read More »
Alerts Sign-up
